Exhibiting a Y-o-Y growth of 5.4%, the global aortic endograft market size is expected to reach USD 3,430.3 million in 2024. Over the forecast period, global demand for aortic endografts is poised to grow at 4.9% CAGR. By 2034, the global aortic endograft revenue is projected to total USD 5,513.5 million.
| Attribute | Details |
|---|---|
| Base Market Value (2023) | USD 3,255.5 million |
| Estimated Aortic Endograft Market Value (2024) | USD 3,430.3 million |
| Projected Market Size (2034) | USD 5,513.5 million |
| Value CAGR (2024 to 2034) | 4.9% |
Growing prevalence of aortic aneurysms is emerging as a prominent factor driving growth of the aortic endograft market. This is because aortic endografts are often used for treating aortic aneurysms.
Rising adoption of medical treatments like endovascular aneurysm repair (EVAR) to treat abdominal aortic aneurysm (AAA) and other conditions will likely fuel aortic endograft demand. Similarly, increasing health awareness is set to foster market growth.
Open surgery is the standard therapy for aortic stenosis, in which an abdominal incision is made, and a synthetic aortic graft is used to replace the damaged segment of the aorta. On the other hand, EVAR is a less intrusive alternative. Growing need for these procedures due to high prevalence of aortic stenosis and aortic aneurysms is expected to create prospects for the market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Aortic Endograft Market Trends
Global sales of aortic endografts recorded a historic CAGR of 3.6% from 2019 to 2023. The market value for the aortic endograft market was around 5.9% of the global cardiovascular devices market, valued at USD 53,020.7 million.
In the assessment period, the worldwide aortic endograft market is set to grow at 4.9% CAGR. It will likely attain a valuation of USD 5,513.5 million by the end of 2034.
| Historical CAGR (2019 to 2023) | 3.6% |
|---|---|
| Forecast CAGR (2024 to 2034) | 4.9% |
The increasing aging population globally has brought about a surge in the prevalence of aortic diseases, particularly abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). As individuals age, the risk of developing such conditions rises, leading to a growing demand for advanced medical interventions requiring aortic endografts.
Endovascular surgeries have emerged as a significant driver for the aortic endograft market. The world is witnessing a notable demographic shift, with a substantial increase in the aging population. The global population aged 60 and older is expected to double by 2050, reaching nearly 2.1 billion, according to the World Health Organization (WHO).
Aging is a major risk factor for aortic diseases, including aneurysms, which are characterized by the abnormal dilation of the aorta. This is expected to play a key role in driving demand for aortic endografts during the assessment period.
Endovascular surgeries like EVAR have gained prominence as a less invasive alternative to traditional open surgeries for treating aortic diseases. Endovascular aneurysm repair (EVAR) involves the insertion of a stent graft (aortic endograft) through small incisions in the groin, reducing the need for extensive surgical intervention. This approach offers several advantages, including quicker recovery times, reduced postoperative complications, and shorter hospital stays.
The aortic endograft market is poised for continued expansion, fueled by the aging demographic and increasing awareness about minimally invasive treatment options. The ongoing research and development activities aim to enhance the efficacy and safety of endovascular procedures. This will contribute to the market's evolution.
Principal Consultant
Asia Pacific's emerging nations, including China and India, are hotspots for investment potential for aortic endograft manufacturers. This is because of their modern healthcare systems, increased collaborations, and faster growth rates in endovascular diagnostics.
Developing economies often experience an increase in the prevalence of lifestyle-related diseases, such as cardiovascular conditions, including aortic aneurysms. The growing burden of aortic diseases creates a demand for effective and advanced treatment options, driving the acceptance of aortic stent grafting systems.
Economic growth in developing economies often leads to rising affluence among the population. As individuals experience higher disposable incomes, there is an increased capacity for healthcare spending. This financial uplift contributes to the acceptance of advanced medical treatments, including aortic endograft procedures.
Improving economic conditions also coincides with increased health insurance penetration in developing economies. As more individuals gain access to insurance coverage, the financial barriers to accessing advanced medical interventions are mitigated, fostering greater acceptance.
To increase revenue share, medical device manufacturing companies are focusing on developing novel aortic stent grafts, such as abdominal aortic stent grafts and thoracic aortic stent grafts. This will bode well for the aortic endograft market.
Increasing demand for aortic stent grafts from end users, such as hospitals and ambulatory surgical centers, for better output and performance will generate opportunities for companies. To capitalize on this, key players are expected to launch novel aortic stent graft products in the market over the long run.
The increasing acceptance of aortic stent grafting systems in developing economies is expected to continue shaping the future landscape of the aortic endograft market. As these regions experience further economic development, demand for advanced medical treatments and aortic endograft procedures is likely to rise.
Product recall is a significant restraint in the aortic endograft market, and instances like the one involving Cook Medical exemplify the impact of such events in the market. A product recall not only affects the financial standing of manufacturers but also erodes the trust of healthcare professionals and patients, posing challenges to the market's overall growth.
An illustrative example of the impact of product recall is Cook Medical's recall of its thoracic endovascular graft, specifically related to the correction for use in blunt thoracic aortic injury. This recall had consequences for the overall market.
Cook Medical initiated a correction for use, which essentially removed indications for blunt thoracic aortic injury. The correction affected the availability of specific sizes of thoracic endovascular grafts in the market.
The recall had direct implications for the aortic endograft market, particularly in North America. The removal of specific sizes from the market limited the options available for healthcare professionals, potentially affecting patient treatment strategies.
Manufacturers need to implement stringent quality assurance measures to minimize the risk of product defects and recalls. Investing in robust quality control protocols can prevent issues before they reach the market.
The financial implications, loss of credibility, and market share erosion underscore the challenges that manufacturers face. Moving forward, the industry must prioritize quality assurance, regulatory compliance, and transparent communication to navigate and mitigate the impact of product recalls on the aortic endograft market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
This section highlights the aortic endograft market across prominent countries. China and India are predicted to register higher CAGRs of 10.3% and 10.6%, respectively, through 2034. Information provided in this section can help aortic endograft companies expand their presence in nations that can provide lucrative revenue-generation opportunities.
Market Growth Outlook by Key Countries
| Country | Value CAGR |
|---|---|
| United States | 2.7% |
| Germany | 3.2% |
| United Kingdom | 2.4% |
| Japan | 5.9% |
| China | 10.3% |
| India | 10.6% |
The United States dominates the global market for aortic endografts, and the trend is expected to continue through 2034. This is due to growing incidence of aortic aneurysms and other diseases, availability of innovative aortic stent grafts, and adoption of advanced aneurysm treatment technologies.
As per the latest report, the United States aortic endograft market size is poised to reach USD 1,231.9 million in 2033. Over the forecast period, demand for aortic endografts in the United States will likely grow at 2.7% CAGR.
The incidence of aortic aneurysms and associated disorders has increased significantly during the last few years. For instance, as per the Centers for Disease Control and Prevention (CDC), around 9,904 people in the United States died due to aortic aneurysm or aortic dissections in 2019. This is expected to create a conducive environment for the aortic endograft industry.
Another key factor expected to boost the United States aortic endograft share is the growing popularity of minimally invasive procedures. When compared to open surgery, minimally invasive techniques frequently yield quicker recovery periods, less discomfort, and lower morbidity.
China aortic endograft market is poised to register a robust CAGR of 10.3% during the forecast period. Overall sales of aortic endografts in China are estimated to be valued at USD 422.3 million in 2033.
The need for aortic endografts is driven by China's growing aging population, which increases the prevalence of aortic illnesses and aneurysms. Aortic endograft demand as a less invasive substitute for conventional surgical treatments is also increasing due to rising awareness of aortic illnesses and the availability of cutting-edge treatment alternatives.
Modern aortic endograft technologies are adopted because of China's dedication to technological breakthroughs in the medical profession. It is drawing in both domestic and foreign producers due to lax government regulations and robust technological growth.
Growing need for endovascular aneurysm repair and high adoption of advanced aortic endograft systems will further boost China market. Subsequently, continuous aneurysm treatment advancements are expected to expand China’s aortic stent graft market size.
India is anticipated to emerge as one of the most lucrative markets for aortic endograft manufacturers during the forecast period. This is due to rising cases of aortic disorders, growing health awareness, and favorable government support. As per the latest report, India aortic endograft market is set to advance with an impressive CAGR of 10.6% through 2034.
In India, aging populations are frequently linked to aortic disorders, such as thoracic aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA). The need for aortic endografts may increase as the population ages and the incidence of these illnesses rises.
Technological developments in aortic endografts, including better delivery systems, materials, and designs, can increase operation safety and efficacy. Newer technologies may be more likely to be adopted by surgeons and healthcare providers, which would accelerate market expansion.
Greater public and healthcare professional knowledge about aortic disorders and available treatments may aid premature detection and action. Increased demand for aortic endografts may result from increased case identification brought about by improved diagnostic capabilities.
The below section provides profound insights into leading segments and their respective shares in the aortic endograft market. This information can help companies to invest in demanding products and find the most profitable end users for their business.
Market Growth Outlook by Key Products
| Product | Value CAGR |
|---|---|
| Abdominal Aortic Grafts | 4.8% |
| Thoracic Aortic Grafts | 7.2% |
Abdominal aortic grafts are expected to retain their dominance in the global endovascular device industry during the forecast period. As per the latest analysis, sales of abdominal aortic grafts will likely rise at 4.8% CAGR through 2034.
The target segment is set to account for a revenue share of 86.8% in 2024. This is attributable to rising prevalence of abdominal aortic aneurysms (AAA) and growing need for treating this health condition globally.
Abdominal aortic endografts have become life-saving solutions for patients suffering from AAA. These medical devices are used to replace a damaged or weakened section of the abdominal aorta.
Increasing incidence of AAA globally is expected to elevate abdominal aortic endograft demand through 2034. Similarly, rising popularity of minimally invasive procedures will further boost the target segment.
Minimally invasive methods, such as endovascular surgery, which requires fewer incisions than open surgery, are frequently used to implant abdominal aortic grafts. This less invasive method can lead to quicker recuperation periods, shorter hospital stays, and less money spent on medical treatment overall.
When compared to open surgical repair, minimally invasive methods involving abdominal aortic grafts are linked to decreased rates of morbidity and mortality. They are, therefore, a better option, particularly for those who, because of their age or other medical issues, could be deemed too risky for standard surgery.
Market Growth Outlook by Key Material
| Materials | Value CAGR |
|---|---|
| Metallic Endografts | 4.8% |
| Polymeric Endografts | 5.3% |
As per the latest aortic endograft industry analysis, polymeric endografts are set to witness a higher demand in the market. This can be attributed to their flexibility and reduced risk of complications.
Polymeric materials are generally more pliable and conformable than metallic materials. This flexibility makes it possible to handle complicated and anatomically difficult cases by facilitating easier navigation through twisted anatomy.
Polymeric aortic endografts can be more discreet than their metallic counterparts. This reduced profile makes minimally invasive operations easier and helps deliver and install the endograft through vessels with a smaller diameter.
The lower thrombogenicity of polymeric endografts is another key factor increasing their popularity. This improves the graft's long-term patency and lowers the chance of blood clot development.
The polymeric endografts segment is anticipated to total USD 2,188.9 million in 2024. Over the assessment period, demand for polymeric endografts will likely rise at 5.3% CAGR. To benefit from this, key aortic endograft manufacturers will look to upgrade their polymeric endograft portfolios.
Market Growth Outlook by Key Procedure
| Procedure | Value CAGR |
|---|---|
| Open Surgical Repair | 4.5% |
| Endovascular Aneurysm Repair (EVAR) | 5.5% |
Based on procedure, the endovascular aneurysm repair (EVAR) segment is expected to lead the aortic endograft market through 2034. It will likely advance with a CAGR of 5.5% throughout the forecast period. This is due to growing preference for minimally invasive procedures for treating aortic aneurysms.
EVAR is a less invasive method of treating aortic aneurysms than open surgery. Rather than creating a huge belly incision, this less invasive method usually entails making minor incisions in the groin area to access the blood arteries.
Compared to open surgical treatments, patients opting for EVAR typically have shorter hospital stays and faster recovery durations. They can resume regular activities sooner, thanks to EVAR's minimally invasive nature.
Research indicates that endoscopic vein grafting (EVAR) is linked to reduced mortality rates when contrasted with open surgical repair, especially in individuals who are deemed more susceptible to problems. Hence, the target segment will play a key role in molding growth of the aortic endograft market over the forecast period.
Market Growth Outlook by Key End User
| End User | Value CAGR |
|---|---|
| Hospitals | 4.4% |
| Ambulatory Surgical Centers | 6.0% |
Hospitals remain the leading end users of aortic endografts. This is attributable to increasing patient footfall, rising number of surgeries in hospitals, and availability of advanced facilities in hospital settings. The target segment is projected to expand at 4.4% CAGR during the assessment period, holding a market share of 56.0% in 2024.
Procedures for aortic endografts are frequently complicated and necessitate specialist medical facilities, which are usually found in hospitals. These facilities include hybrid operating rooms and catheterization labs. These institutions have the cutting-edge surgical and imaging equipment required for endovascular operations.
Specialized healthcare workers with training and experience in executing aortic endograft treatments, such as vascular surgeons and interventional radiologists, are typically available in hospitals. The effectiveness of these interventions depends on this knowledge.
Innovation is becoming a key focus of leading manufacturers of aortic endografts to stay ahead in this industry. They are constantly investing in research and development to introduce novel products with enhanced features like biocompatibility and durability. Partnership and collaboration are also a priority for top aortic endograft manufacturers.
Recent Developments in the Aortic Endograft Market:
| Attribute | Details |
|---|---|
| Estimated Value Market (2024) | USD 3,430.3 million |
| Projected Aortic Stent Graft Market Size (2034) | USD 5,513.5 million |
| Anticipated Growth Rate (2024 to 2034) | 4.9% CAGR |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | Europe; North America; Latin America; Asia Pacific and Middle East & Africa |
| Key Countries Covered | United States, Japan, United Kingdom, Germany, France, Italy, Spain, Russia Poland, BENELUX, Nordic Countries, Canada, Mexico, Brazil, Chile, India, ASEAN Countries, China, South Korea, Australia, New Zealand, Saudi Arabia, Israel, Other African Union, South Africa |
| Key Market Segments Covered | Product, Material, Procedure, End User, and Region |
| Key Companies Profiled | Medtronic; Cook; W. L. Gore & Associates, Inc.; Braile Biomédica; Cordis Corporation; Endologix LLC; Endospan; LifeTech Scientific; MicroPort Scientific Corporation; Terumo Corporation |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global aortic endograft market size is set to reach USD 3,430.3 million in 2024.
Global demand is projected to increase at 4.9% CAGR through 2034.
The aortic endograft market value is expected to total USD 5,513.5 million by 2034.
Abdominal aortic grafts segment leads the target market.
The global market increased at a 3.6% CAGR from 2018 to 2023.
The United States accounted for around 29.9% share of the global market in 2022.
Aortic endografts are mostly used to treat aneurysms.
Abdominal aorta.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value-Added Insights 5. Market Background 6. Global Market Demand (in Volume) Analysis 2019 to 2023 and Forecast, 2024 to 2034 7. Global Market - Pricing Assessment 8. Global Market Demand (in Value or Size in USD Million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 9.1. Abdominal Aortic Graft 9.2. Thoracic Aortic Graft 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Procedure 10.1. Open Surgical Repair 10.2. Endovascular Aneurysm Repair (EVAR) 10.2.1. Standard EVAR 10.2.2. Fenestrated EVAR 10.2.3. Branched EVAR 10.2.4. Chimney EVAR 10.2.5. Snorkel EVAR 10.2.6. Hybrid EVAR 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Material 11.1. Metallic Endograft 11.1.1. Stainless Steel 11.1.2. Nitinol 11.2. Polymeric Endograft 11.2.1. Dacron 11.2.2. ePTFE 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 12.1. Hospitals 12.1.1. Private Hospitals 12.1.2. Public Hospitals 12.2. Ambulatory Surgical Centers 13. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 13.1. United States 13.2. Japan 13.3. Europe 13.4. North America 13.5. Latin America 13.6. East Asia 13.7. Asia-Pacific 13.8. Middle East & Africa 14. United States Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15. Japan Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18. Asia-Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034 19. Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 20. Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 21. Market Structure Analysis 22. Competition Analysis 22.1. Medtronic plc. 22.2. Cook Medical 22.3. W. L. Gore & Associates, Inc. 22.4. Braile Biomédica 22.5. Cordis Corporation 22.6. Endologix LLC 22.7. Endospan 22.8. LifeTech Scientific 22.9. MicroPort Scientific Corporation 22.10. Terumo Corporation 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Aortic Endograft Market
